Imv Inc (TSE:IMV) – Research analysts at Oppenheimer issued their Q1 2020 EPS estimates for shares of IMV in a research report issued on Monday, December 9th. Oppenheimer analyst J. Olson expects that the company will post earnings per share of ($0.13) for the quarter. Oppenheimer has a “Outperform” rating and a $9.00 price target on the stock. Oppenheimer also issued estimates for IMV’s Q2 2020 earnings at ($0.12) EPS, Q3 2020 earnings at ($0.16) EPS and Q4 2020 earnings at ($0.11) EPS.
IMV (TSE:IMV) last issued its earnings results on Friday, November 8th. The company reported C($0.16) earnings per share for the quarter, missing the consensus estimate of C($0.12) by C($0.04). The firm had revenue of C$0.16 million for the quarter, compared to analyst estimates of C$0.06 million.
IMV Inc, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.
Featured Story: Preferred Stock
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.